Federal Regulatory Snapshot for Dietary Supplements (2026)

Source check: March 13, 2026 | Revalidate by: March 27, 2026

This guide separates what is enforceable federal law today from what is still only proposed legislation or policy rhetoric. It also removes stale enforcement statistics that could not be supported by primary official sources on March 13, 2026.

For brand operators, the practical baseline remains the same: follow FDA and FTC claims rules, keep substantiation organized, and treat new bills as proposals until Congress advances them.

Dietary supplement manufacturers must comply with 21 CFR Part 111 (Current Good Manufacturing Practice for dietary supplements). This includes requirements for personnel, facilities, equipment, production, laboratory operations, and record-keeping.

Proposed Bills: Important, but Not Current Law

S.3677 — Dietary Supplement Listing Act of 2026

Congress.gov lists S.3677 as introduced in the Senate on January 15, 2026 and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill would create a mandatory product listing framework for dietary supplements, but it is not currently operative law.

H.R.7366 — House preemption proposal

Congress.gov lists H.R.7366 as introduced in the House on February 4, 2026 and referred to committee. It matters because it would affect state-level supplement restriction conflicts, but it is also still only a proposal.

Operational takeaway: prepare for possible listing or preemption changes, but do not represent these bills as current legal requirements until Congress advances them.

MAHA: What Has Actually Happened

The Make America Healthy Again (MAHA) movement is the single biggest force reshaping supplement regulation in 2026. But separating concrete agency actions from political messaging takes work. Here is what has actually moved.

FDA 2026 Priority Deliverables (published January 2026)

The FDA's Human Foods Program published its 2026 priority list, and two items stand out for supplement operators:

GRAS reform: a proposed rule would require mandatory notice of self-affirmed GRAS substances. A draft rule was sent to OMB in December 2025. If finalized, this would eliminate GRAS self-affirmation entirely, meaning companies could no longer quietly declare their own ingredients as "generally recognized as safe."
NDI guidance: FDA committed to releasing final guidance on safety and identity information required for NDI notifications. This has been in draft form for years, and a final version would clarify what evidence manufacturers actually need to submit.

Concrete actions taken so far

Synthetic food dye phase-out accelerated, with all synthetic food dyes targeted for removal by the end of 2026.
14 of 19 previously banned peptides were made legally available through compounding pharmacies.
Proposals to allow supplements to be covered by Medicare, SNAP, and HSAs are being actively pushed.
$234.6 million was earmarked for MAHA priorities in the FY2026 federal budget.

The paradox brand operators need to understand

MAHA wants more supplement oversight. At the same time, FDA lost 3,859 employees in 2025 and another 473 in early 2026 under DOGE workforce reductions. The FY2026 budget allocates $6.8 billion to FDA, a $271 million decrease from FY2025. The agency is being asked to do more with less. For manufacturers, this means the rules on paper may tighten while the people who enforce those rules shrink in number. Do not assume fewer inspectors means less enforcement risk. FDA has historically responded to staffing gaps by concentrating resources on high-profile enforcement actions that generate headlines and industry deterrence.

Sources: FoodNavigator-USA (Feb 2026), BioPharma Dive, FDA FY2026 budget documents

State-Level Regulation: The Growing Patchwork

While federal bills move slowly, several states are pushing ahead with their own supplement restrictions. The most active area is age restrictions on sales of weight loss and muscle building products.

Hawaii introduced a bill to prohibit the sale of weight loss and muscle building supplements to minors. It passed its initial committee review.
Rhode Island filed a similar bill as of March 12, 2026.
Similar bills have been filed in Alaska, Massachusetts, Michigan, and Washington.

The Natural Products Association (NPA) has publicly stated it is "redoubling efforts" to defeat age restriction bills at the state level. The federal H.R.7366 bill (covered above) would preempt these state restrictions if it passes, but that bill remains in committee. Until it advances, brands selling weight management or sports nutrition products should track legislation in their key sales states.

Sources: SupplySide (2026), NutraIngredients (March 10, 2026)

Enforceable Federal Baseline Right Now

FTC substantiation rules

FTC's Health Products Compliance Guidance remains one of the clearest primary sources for supplement advertising risk. FTC says marketers need competent and reliable scientific evidence for health-related claims, and the agency's 2023 notice campaign warned almost 700 companies that unsupported claims can trigger penalties if prior notice doctrines apply.

FTC penalty exposure

FTC's 2025 inflation adjustment raised the relevant maximum civil penalty to $53,088. That is the current figure to cite, as the older $50,120 amount from 2024 still appears in many third-party summaries.

FDA structure/function claim rules

FDA's structure/function claims page remains the primary official reference for supplement claims basics. In general, a dietary supplement may use structure/function claims if the claim is truthful and not misleading, the required FDA disclaimer is used when applicable, and the manufacturer notifies FDA within 30 days after first marketing the product with that claim.

Amazon as a de facto regulator

In December 2025, Amazon expanded its cGMP documentation requirement to all supplement categories sold on the platform. While this is not federal law, it affects more supplement sellers than any single FDA enforcement action in recent years. Brands that sell through Amazon should treat cGMP documentation as a baseline operating requirement, not an optional checkbox. For a detailed walkthrough, see our Amazon supplement compliance guide.

What this means in practice: the fastest way to reduce near-term regulatory risk is still a disciplined claims review process tied to substantiation files, label copy, Amazon listings, and social posts.

What This Guide Does Not Treat as Settled Fact

Unverified monthly warning-letter trendlines that are not grounded in current FDA primary-source counts.
Speculative MAHA forecasts beyond the concrete actions and published FDA priorities documented above.
Older FTC penalty figures that were superseded by the 2025 inflation adjustment.

Primary Sources Checked

Source check completed on March 13, 2026. Re-check before using this page for a board memo, investor update, or legal compliance decision.

Concepts Covered

DSHEA (Dietary Supplement Health and Education Act)FDA Facility Registration FDA Inspection FDA Warning Letter Structure/Function Claims NDI (New Dietary Ingredient)